MK-8745 NEW
| Price | $34 | $51 | $91 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: MK-8745 | CAS No.: 885325-71-3 |
| Purity: 99.31% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | MK-8745 |
| Description | MK-8745 is a potent and selective Aurora A inhibitor. |
| In vivo | MK-8745 induces apoptosis in a p53-dependent manner across various cell lines in vitro. Exposure of p53 wild-type cells to MK-8745 leads to the induction of p53 phosphorylation (ser15) and an increase in p53 protein expression. This p53-dependent apoptotic effect of MK-8745 is further confirmed in HCT 116 p53 (-/-) cells transfected with wild-type p53. In non-Hodgkin's lymphoma cell lines, MK-8745 causes cell cycle arrest at the G2/M phase with the accumulation of tetraploid nuclei, followed by cell death. Treatment with MK-8745 induces p21 (waf1/cip1) and CycB1, indicating cell cycle arrest and an increased population of cells in the G2/M phase. Additionally, MK-8745 treatment leads to the rapid degradation of Aurora-A substrates (TACC3, Eg5, and TPX2) following the reduction of phospho-Aurora-A. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 1 mg/mL (2.31 mM) DMSO : 55 mg/mL (127.34 mM), Sonication is recommended. |
| Keywords | MK8745 | Inhibitor | inhibit | Aurora Kinase | Apoptosis | MK-8745 | MK 8745 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Highly Selective Inhibitor Library | Apoptosis Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY